		Potent and Trademark Office; U.S DEPARTMENT OF COMMERCE
Substitute for form 1449A/PTO		COMPLETE IF KNOWN
INFORMATION DISCLOSURE  PETATEMENT BY APPLICANT  MAY 28 THE Many sheets as necessary)	Application Number	10/527,561
TEMENT DV ADDI ICANT	Filing Date	March 11, 2005
EMENT BY AFFLICANT	First Named Inventor	I.E. Kopka et al.
P , 191\	Group Art Unit	
na 1 % wase to many sneets as necessary)	Examiner Name	
of 4	Attorney Docket Number	21204P
	INFORMATION DISCLOSURE  PETATEMENT BY APPLICANT  many sheets as necessary)	INFORMATION DISCLOSURE  Application Number  Filing Date  First Named Inventor  Group Art Unit  Examiner Name

	U.S. PATENT DOCUMENTS										
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY						
1/13		5684011		Fitzjohn et al.	11/04/1997						
<i>YY</i> )		5462960		Barth et al.	10/31/1995						
W)		5624941		Barth et al.	04/29/1997						
W		2002/0004600		Meyer et al.	01/10/2002						
M		2004/0259887		Dow	12/23/2004						
					***						
			<u> </u>								
			<u> </u>								
			<u> </u>								
			_1		L						

			FORE	IGN PATENT	DOCUMENTS	_
	<b>~</b> :.	Fo	reign Patent Docume	nt		Date of Publication of
1	Cite No.	Office	Office Number		Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
M	<u> </u>	EP 0 570	6 357		Sanofi	03/05/1997
		EP 0 65	6 354		Sanofi	06/04/1997
		WO 200	4/111039		AstraZeneca AB	12/23/2004
		WO 200	4/111033	•	AstraZeneca AB	12/23/2004
		WO 200	4/111034		AstraZeneca AB	12/23/2004
		WO 200	4/111038		AstraZeneca AB	12/23/2004
		WO 200	5/000817		Sanofi-Aventis	01/06/2005
		WO 200	4/037823		Pfizer Products Inc.	05/06/2004
		WO 200	4/012671		Merck & Co., Inc.	02/12/2004
M		WO 200	4/110453		Pfizer Products Inc.	12/23/2004

Examiner Signature Date Considered 10/30/07

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form \* IDS Form\* (IDS Folder), Merck & Co., Inc., 09/05/2003

	_				Patent and Trademark Office; U.S DEPARTMENT OF COM	IMERCE
	Substitute for form 1449A/P	то		(	COMPLETE IF KNOWN	
Ì	INFORMATIO	ASEMENT BY APPLI	OSURE	Application Number	10/527,561	,
	ENCHENIT	DWADDI	ICANT	Filing Date	March 11, 2005	
Q.	Ψ.λ	DI AFFI	ACANI	First Named Inventor	I.E. Kopka et al.	
70	29 mm E	(used many sheets as necessary)	,	Group Art Unit		
ν,"	(uses many s		ssary)	Examiner Name		
SI	icot 2	of	4	Attorney Docket Number	21204P	
_						

	U.S. PATENT DOCUMENTS										
Examiner Initials*	Cite No.	U.S. Patent Docume Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY						

	FOREIGN PATENT DOCUMENTS										
1		~·	For	eign Patent Documer	nt		Date of Publication of				
Examiner Cite Initials* No. Office	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY						
V	<u>ဂ</u>		WO 2005	6/020992		Solvay Pharmaceuticals GmbH	03/10/2005				
			WO 2005	/016286		Bristol-Myers Squibb Company	02/24/2005				
			WO 2003	/084943		Sanofi-Synthelabo	10/16/2003				
			WO 03/0	27076		Solvay Pharmaceuticals B.V.	04/03/2003				
			WO 2004	/035566		Pfizer Products Inc.	04/29/2004				
			WO 2004	/094421		Pfizer Products Inc.	11/04/2004				
			WO 03/0	51850		AstraZeneca AB/AstraZeneca UK Limited	06/26/2003				
			WO 03/0	51851		AstraZeneca AB/AstraZeneca UK Limited	06/26/2003				
	$\coprod$		WO 2004	/105699		Pharmacia Corporation	12/09/2004				
V	$\langle \rangle$		WO 2004	/018433		Glaxo Group Limited	03/04/2004				

Examiner Signature Date Considered 10(3010 M

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	COMPLETE IF KNOWN
Application Number	10/527,561
Filing Date	March 11, 2005
First Named Inventor	I.E. Kopka et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21204P
	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name

U.S. PATENT DOCUMENTS									
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (known)	Name of Patentee or Applicant Octed Document Of Cited Document MM-DD-YYYY					

	FOREIGN PATENT DOCUMENTS										
	<b>~</b> :.		Foreign Patent Docume	nt	_	Date of Publication of					
Examiner Cite Initials* No. Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY							
W			WO 2004/052864		Pfizer Products Inc.	06/24/2004					
		,	WO 98/37061		Bayer Aktiengesellschaft	08/27/1998					
			WO 03/002114		AB Science	01/09/2003					
			WO 03/006007		Research & Innovation Soc. Coop. A R.L.	01/23/2003					
			WO 98/32441		Sanofi	07/30/1998					
			WO 01/58450		Sanofi-Synthelabo	08/16/2001					
			WO 2005/009479		Merck & Co., Inc.	02/03/2005					
W			WO 03/000787		The Nisshin Oil Mills, Ltd/Ina Food Industry Co., Ltd.	03/01/2003					
	_										

Examiner Signature Date Considered W0 (30 07)

 COMPLETE IF KNOWN	С			notify do for form 1440B/DTO		
 10/527,561	Application Number	CLOSURE	Substitute for form 1449B/PTO INFORMATION DISCLOSURE E STATEMENT BY APPLICANT 2 9 7005 (use smany sheets as necessary)			
March 11, 2005	Filing Date	STATEMENT BY APPLICANT				
I.E. Kopka et al.	First Named Inventor	LICANI	I AF			
	Group Art Unit	29 700 5			MAK ,	
	Examiner Name	cessary)	(use symany sheets as necessary)			
 21204P	Attorney Docket Number	4	of	4	Sheet	
	Group Art Unit Examiner Name		ets as ne	م عسد قا	NPR STORY	

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
m	AA	Le Foll et al., J. Pharm. & Exper. Ther., Vol. 312 (2005), pp. 875-883, "Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence"
VD	AB	Lange et al., J. Med. Chem., pp. A-P, "Bioisosteric replacements of the pyrazole moiety of rimonabant  48(6), 1823 - 1839, 2005
m	AC	Piomelli et al., Trends in Pharma. Sci., Vol. 21 (2000), pp. 218-224, "The endocannabinoid system as a target for therapeutic drugs"
M	AD	Goya et al., Exp. Opin. Ther. Patents, Vol. 10 (2000), pp. 1529-1538, "Recent advances in cannabinoid receptor agonists and antagonists"
M	AE	Xiang et al., Ann. Reports in Med. Chem., Vol. 34 (1999), pp. 199-208, "Chap. 20. Pharmacology of cannabinoid receptor agonists and antagonists"
Uŋ	AF	Barth, Exp. Opin. Ther. Patents, Vol. 8 (1998), pp. 301-313, "Cannabinoid receptor agonists and antagonists"
W)	AG	Rinaldi-Carmona et al., Life Sciences, Vol. 56 (1995), pp. 1941-1947, "Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"
Щ	АН	Rinaldi-Carmona et al., FEBS Letters, Vol. 350 (1994), pp. 250-244, "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"
M	AI	Hetzheim et al., Pharmazie, Vol. 40(1) (1985), pp. 17-20, "Ringtransformation von O,N-heterocyclen"

Examiner Signature Date Considered 10/30/07	$\overline{}$							
Signatura     Y / S  4. $  Y     S  $ 4. $  S  $	Evaminer	1 \ /	^ ^		D			
Signature	CVALIBLE	1 1./	15 0.	1	Date		1	1 = ~ 4
	Signature	1 1 /	(i) $(i)$	1 A	Considered	1.0	ノスカル	1 11 17
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	31811212	-		War.	Considered		ו שט ו	